FogPharma
FogPharma is a clinical-stage company pioneering a new class of drugs to address the limitations of today’s precision medicines, with its lead program FOG-001 currently in Phase 1/2 clinical trials.
Company Overview
FogPharma is a clinical-stage company pioneering a new class of drugs designed to address the limitations of current precision medicines, striving for universal druggability. The company's headquarters are located at Cambridge Discovery Park, 30 Acorn Park Drive, Cambridge, MA 02140. FogPharma's innovative approach integrates cutting-edge technologies to accelerate drug discovery and development, making strides in areas previously considered 'undruggable.'
Drug Discovery and Technologies
FogPharma's discovery engine utilizes advanced technologies such as directed evolution, proprietary α-helix conformational hyperstabilization chemistry, and highly multiplexed drug optimization technology. The company's Helicons, combining the targeting strength and specificity of antibodies with the intracellular target engagement and broad tissue distribution of small molecules, are a cornerstone of its discovery efforts. This unique technological approach aims to dramatically improve the speed and scalability of drug discovery.
Lead Programs and Pipeline
FOG-001, FogPharma’s leading program, is a first-in-class TCF-blocking β-catenin inhibitor currently in Phase 1/2 clinical trials. The pipeline includes programs targeting major cancer drivers: the ERG program for ERG-fusion-positive prostate cancers, a Cyclin E1/2 degrader program for chemotherapy-resistant tumor types, and a pan-RAS program focusing on gain-of-function mutations in the RAS family of oncogenes found in approximately 25% of human cancers. The company also collaborates with ARTBIO on Helicon-enabled alpha radioligand therapies for cancer treatment.
Financing and Collaborations
FogPharma has successfully secured significant financing to support its initiatives, including a $178 million Series D round to advance its Helicon polypeptide therapeutics and a $107 million Series C financing to further its Universal Druggability™ platform and direct β-catenin antagonist. Additionally, the company announced $145 million in funding for the clinical development of FOG-001 and its Helicon peptide portfolio. Strategic collaborations include a partnership with ARTBIO to co-develop cancer treatments.
Recognition and Awards
FogPharma has been recognized in the biotechnology industry for its innovative approach. In 2023, the company was named one of the “Fierce 15” Biotech Companies by Fierce Biotech, highlighting its contributions and potential impact within the field. This acknowledgment underscores FogPharma’s commitment to advancing therapeutic frontiers in precision medicine.